文献速递生殖医学

如何识别可从延迟成熟卵母细胞受精中获益的患者:一项同胞卵母细胞与倍性结局研究

How to identify patients who would benefit from delayed-matured oocytes insemination: a sibling oocyte and ploidy outcome study.
PubMed 文献 · Hum Reprod · 2023-01-01

该观察性研究纳入2019年1月至2021年6月共469个卵巢刺激周期的5449个卵丘卵母细胞复合体,比较延迟成熟卵母细胞(MII-D1)与同胞成熟卵母细胞(MII-D0)的受精率、囊胚利用率和整倍体率。结果显示MII-D0受精率和囊胚利用率显著高于MII-D1,但整倍体率无显著差异。高龄、低成熟率和/或低受精率患者中,延迟成熟卵母细胞对可活检囊胚队列贡献≥50%。

要点

  • MII-D0受精率69.5%显著高于MII-D1的55.9%(P<0.001)。
  • MII-D0囊胚利用率59.5%显著高于MII-D1的18.5%(P<0.001)。
  • MII-D0与MII-D1整倍体率46.3%对39.0%无显著差异(P=0.163)。

核心结论

  • 延迟成熟卵母细胞在高龄、低成熟率和/或低受精率患者中对可活检囊胚队列贡献≥50%。
  • MII-D0与MII-D1的整倍体率无显著差异(46.3%对39.0%,P=0.163)。

研究设计与样本

  • 观察性研究,2019年1月至2021年6月,共469个卵巢刺激周期、5449个卵丘卵母细胞复合体。
  • 同胞对照:ICSI成熟卵母细胞2911个和IVF成熟卵母细胞544个为MII-D0,延迟成熟卵母细胞910个为MII-D1。
  • 纳入390名IVF/ICSI患者,取卵日至少有一个MI或GV卵母细胞且在剥卵后20-28小时成熟。
  • 仅纳入计划使用新鲜自体卵母细胞进行非整倍体植入前遗传学检测的周期。

主要发现

  • 受精率:MII-D0 69.5% vs MII-D1 55.9%,P<0.001。
  • 囊胚利用率:MII-D0 59.5% vs MII-D1 18.5%,P<0.001。
  • 整倍体率:MII-D0 46.3% vs MII-D1 39.0%,P=0.163,无显著差异。
  • MII-D1贡献≥50%可活检囊胚的患者特征:高龄(平均年龄37.7岁)、获卵<10个且成熟率<34%、受精率<60%。
  • MII-D1中每注射一个MII卵母细胞增加获得整倍体胚胎的几率(OR=1.83,CI:1.50-2.24,P<0.001);MII-D1-GV成熟组OR=1.78(CI:1.42-2.22,P<0.001),MII-D1-MI成熟组OR=1.54(CI:1.25-1.89,P<0.001)。

关键数值与推荐

  • 高龄、获卵<10个且成熟率<34%、受精率<60%的患者中,延迟成熟卵母细胞对可活检囊胚队列贡献≥50%。
  • MII-D1组中每注射一个MII卵母细胞,获得整倍体胚胎的OR=1.83(CI:1.50-2.24,P<0.001)。

临床怎么用

  • 作者认为研究结果可能为IVF实验室提供指导,以筛选可从MII-D1 ICSI中获益的患者人群,避免不必要的成本和工作量。

局限性

  • MII-D1的ICSI使用前一日的新鲜或冷冻精液或睾丸样本进行。
  • 未确定延迟成熟MI/GV卵母细胞极体排出的确切时间。
  • 未能确定未成熟卵母细胞最终成熟至MII的时间点以及IVF受精卵母细胞的成熟时间点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which patients might benefit from insemination of delayed-matured oocytes? SUMMARY ANSWER: Delayed-matured oocytes had a ≥50% contribution to the available cohort of biopsied blastocysts in patients with advanced maternal age, low maturation, and/or low fertilization rates. WHAT IS KNOWN ALREADY: Retrieved immature oocytes that progress to the MII stage in vitro could increase the number of embryos available during ICSI cycles. However, these delayed-matured oocytes are associated with lower fertilization rates and compromised embryo quality. Data on the ploidy of these embryos are controversial, but studies failed to compare euploidy rates of embryos derived from delayed-matured oocytes to patients' own immediate mature sibling oocytes. This strategy efficiently allows to identify the patient population that would benefit from this approach. STUDY DESIGN, SIZE, DURATION: This observational study was performed between January 2019 and June 2021 including a total of 5449 cumulus oocytes complexes from 469 ovarian stimulation cycles, from which 3455 inseminated matured oocytes from ICSI (n = 2911) and IVF (n = 544) were considered as the sibling controls (MII-D0) to the delayed-matured oocytes (MII-D1) (n = 910). Euploidy rates were assessed between delayed-matured (MII-D1) and mature sibling oocytes (MII-D0) in relation to patients' clinical characteristics such as BMI, AMH, age, sperm origin, and the laboratory outcomes, maturation, fertilization, and blastocyst utilization rates. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 390 patients undergoing IVF/ICSI, who had at least one metaphase I (MI) or germinal-vesicle (GV) oocyte on the day of oocyte collection (Day 0), which matured in 20-28 h after denudation were included. MI and GV oocytes that matured overnight were inseminated on the following day (Day 1, MII-D1) by ICSI. Only cycles planned for preimplantation genetic testing for aneuploidy using fresh own oocytes were included. MAIN RESULTS AND THE ROLE OF CHANCE: Fertilization (FR) and blastocyst utilization rates were significantly higher for MII-D0 compared to delayed-matured oocytes (MII-D1) (69.5% versus 55.9%, P < 0.001; and 59.5% versus 18.5%, P < 0.001, respectively). However, no significant difference was observed in the rate of euploid embryos between MII-D0 and MII-D1 (46.3% versus 39.0%, P = 0.163). For evaluation of the benefit of inseminating MI/GV oocytes on D1 per cycle in relation to the total number of biopsied embryos, cycles were split into three groups based on the proportion of MII-D1 embryos that were biopsied in that cycle (0%, 1-50%, and ≥50%). The results demonstrate that patients who had ≥50% contribution of delayed-matured oocytes to the available cohort of biopsied embryos were those of advanced maternal age (mean age 37.7 years), <10 oocytes retrieved presenting <34% maturation rate, and <60% fertilization rate. Every MII oocyte injected next day significantly increased the chances of obtaining a euploid embryo [odds ratio (OR) = 1.83, CI: 1.50-2.24, P < 0.001] among MII-D1. The odds of enhanced euploidy were slightly higher among the MII-D1-GV matured group (OR = 1.78, CI: 1.42-2.22, P < 0.001) than the MII-D1-MI matured group (OR = 1.54, CI: 1.25-1.89, P < 0.001). Inseminating at least eight MII-D1 would have >50% probability of getting a euploid embryo among the MII-D1 group. LIMITATIONS, REASONS FOR CAUTION: ICSI of MII-D1 was performed with the fresh or frozen ejaculates or testicular samples from the previous day. The exact timing of polar body extrusion of delayed-matured MI/GV was not identified. Furthermore, the time point of the final oocyte maturation to MII for the immature oocytes and for the oocytes inseminated by IVF could not be identified. WIDER IMPLICATIONS OF THE FINDINGS: The results of this study might provide guidance to the IVF laboratories for targeting the patient's population who would benefit from MII-D1 ICSI without adhering to unnecessary costs and workload. STUDY FUNDING/COMPETING INTEREST(S): No external funding was received for this study. There are no conflicts of interest to be declared for any of the authors. There are no patents, products in development, or marketed products to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Elkhatib I, Nogueira D, Bayram A, et al. How to identify patients who would benefit from delayed-matured oocytes insemination: a sibling oocyte and ploidy outcome study. Hum Reprod. 2023. PMID: 37344149. doi:10.1093/humrep/dead129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。